Display options
Cite
Virchow JC, Li VW, Fonseca E, et al. Chronic cough in Germany: results from a general-population survey. ERJ Open Res. 2022;8(1)doi: 10.1183/23120541.00420-2021.
Virchow, J. C., Li, V. W., Fonseca, E., Salmen, H., Martin, A., Brady, J., Jannowitz, C., & Schelfhout, J. (2022). Chronic cough in Germany: results from a general-population survey. ERJ open research, 8(1), . https://doi.org/10.1183/23120541.00420-2021
Virchow, J Christian, et al. "Chronic cough in Germany: results from a general-population survey." ERJ open research vol. 8,1 (2022). doi: https://doi.org/10.1183/23120541.00420-2021
Virchow JC, Li VW, Fonseca E, Salmen H, Martin A, Brady J, Jannowitz C, Schelfhout J. Chronic cough in Germany: results from a general-population survey. ERJ Open Res. 2022 Jan 10;8(1). doi: 10.1183/23120541.00420-2021. eCollection 2022 Jan. PMID: 35036416; PMCID: PMC8752938.
Copy Download .nbib Format: NLM
Share it on

ERJ Open Res. 2022 Jan 10;8(1). doi: 10.1183/23120541.00420-2021. eCollection 2022 Jan.

Chronic cough in Germany: results from a general-population survey.

ERJ open research

J Christian Virchow, Vicky W Li, Eileen Fonseca, Helena Salmen, Ashley Martin, Joanne Brady, Christina Jannowitz, Jonathan Schelfhout

Affiliations

  1. Depts of Pneumology and Intensive Care Medicine, University of Rostock Medical Clinic, Rostock, Germany.
  2. Kantar Health Co., Inc., New York, NY, USA.
  3. Merck & Co., Inc., Kenilworth, NJ, USA.
  4. MSD Sharp & Dohme GmbH, Haar, Germany.

PMID: 35036416 PMCID: PMC8752938 DOI: 10.1183/23120541.00420-2021

Abstract

BACKGROUND: Chronic cough (CC) which is defined ≥8 weeks is a common condition in clinical practice. However, estimates of prevalence and associated comorbidities in German adults and key subgroups of age and gender are lacking.

METHODS: Cross-sectional study based on a representative panel of 15 020 adult subjects of the general population who completed the German National Health and Wellness Survey, reporting CC and questions about comorbidities. Lifetime and 12-month prevalence are presented as unweighted estimates.

RESULTS: The lifetime CC prevalence was 6.5% (range across age groups 5.1%-8.3%) and the 12-month prevalence was 4.9% (range 3.7-5.7%). The prevalence of diagnosed CC was 2.8% (range 0.9-4.1%) and the prevalence of persons currently on any prescription to treat CC was 0.6% (range 0.2-1.4%). Respondents who experienced CC were 52.0±17.0 years old, with a higher prevalence in those aged 50 years and older. Persons with CC had higher morbidity scores and were diagnosed with an increased number of comorbidities, most frequently diagnoses of the respiratory system (71.0%), followed by digestive tract disorders (34.0%) and sleep disorders (37.6%).

CONCLUSIONS: In a broadly representative sample of German adults, lifetime and 12-month prevalence of CC was greatest in current and former smokers and those older ≥50 years of age. Comorbidities are frequent and may complicate management of these patients.

Copyright ©The authors 2022.

Conflict of interest statement

Conflict of interest: J.C. Virchow has the following to disclose: lectured for and received honoraria from AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer Ingelheim, Chiesi, Essex/Schering

Publication Types